MIMETAS

In our latest application note, learn how leveraging the OrganoReady® Colon Organoid can enhance gastrointestinal toxicity predictions in drug development. This innovative model, paired with functional multiplexed assays, offers: ✅ Translatability: Superior physiological relevance through adult stem cell-derived organoids. ✅ Ease of Use: Simplified workflows with a ready-to-use, 3D colon organoid model. ✅ Screenability & Flexibility: Enhanced versatility for robust toxicity screening, enabled by multiplexed assays. Whether you are supporting animal or clinical stage studies, or improving the safety liabilities of early stage lead compounds, this innovative approach delivers a more predictive and efficient solution    📄 Download the full app note: https://lnkd.in/eVPPRczk #DrugDiscovery #Toxicology #Organoids #BiotechInnovation #LifeSciences

We’re proud to revisit this incredible feedback from Philip Hewitt, Early Investigative Toxicology, Pre-clinical Safety at Merck KGaA, Darmstadt, Germany, who highlighted the transformative role of the OrganoTEER® system and the OrganoPlate® platform in their workflows. 💡 In Philip’s words: “The OrganoPlate® platform with the OrganoTEER® system will become a standardized assay in our early investigative toxicology drug screening workflow. With the OrganoPlate, we see a reproducible early screen for intestinal toxicity, and the first example internally of an advanced cell model being implemented into routine testing. To date, the OrganoReady® Caco-2 model is for us, at Merck, the most suitable platform offering at the same time scalability, speed, robustness, ease of handling, with low compound needs.” This testimonial continues to inspire us as we work to empower researchers worldwide with reliable, scalable, and advanced cell models. Want to see how our platform can transform your workflows? 🔗 Learn about the OrganoTEER: https://lnkd.in/eQ2qUYWP 🔗 Explore our offerings: https://lnkd.in/ejpzYH2f #AdvancedCellModels #CustomerTestimonial #LifeSciences #Innovation

Proud to see Queen Mary University of London leading this £1.7 million EPSRC project to transform drug discovery with organ-on-a-chip technology! Traditional models often fall short of predicting human outcomes, but this collaborative project aims to change that by integrating spatial tissue patterning to better mimic human biology. At MIMETAS, we're thrilled to join forces with partners like GSK, UCB-Pharma, and @MHRA to drive safer, more effective drug development. Here’s to faster, more reliable treatments for patients!

Want to keep up with the latest research and expert insights in microphysiological systems? 📈 Sign up for our newsletter and gain exclusive access to: ✅ Insights into advancements in 3D human disease models ✅ Special event invitations and webinars ✅ Updates on our services and products Be part of a community that's shaping the future of healthcare and pharmaceuticals. 🔗Sign up today: https://lnkd.in/eZDjaqbf #LifeSciences #DrugDevelopment #OrganOnAChip #BiomedicalResearch #Innovation

🚀Catch MIMETAS's expert, Nick Saites, PhD, at #DiscoveryUS2024! 🚀Connect with Nick at the conference to learn how MIMETAS can support your drug discovery efforts with our 3D tissue models. He will also be presenting MIMETAS' latest 3D liver model, developed for fibrosis drug discovery and gene delivery applications. This breakthrough model mimics the liver’s complex, multi-cellular structure, capturing both healthy and diseased states. 🕑 Poster Viewing Times Today: 10:45 AM - Networking Break 1:00 PM - Lunch Break Stop by to chat with Nick and discover how MIMETAS is advancing drug discovery with our services! 🔗 Explore our offerings: https://lnkd.in/ehsm8j9E 🔗 Download the poster: https://lnkd.in/eanzwqam #LiverResearch #DrugDiscovery #Pharma #Biotech #LifeSciences

In this recent publication from our customer, they share valuable insights into how protein-bound uremic toxins affects vascular health, particularly relevant for chronic kidney disease research. The researchers leveraged MIMETAS’s technology to simulate complex human vascular environments, allowing them to observe the damaging effects of p-cresol on endothelial integrity and inflammation. This study highlights the value of physiologically relevant models in revealing disease mechanisms that can be difficult to capture with traditional 2D cultures. Read the article here: https://lnkd.in/eRNVxFU4 At MIMETAS, we’re proud to support our customers with customizable 3D organ models that drive impactful research forward. Interested in how our services can support your research goals? Explore our offerings to see how we can help bring your studies closer to real-world clinical applications. 🔗 https://lnkd.in/ejpzYH2f #CRO #CustomerResearch #VascularHealth #Biotech #Innovation

Streamline your gut toxicity research with OrganoReady® Colon Organoid— an innovative model designed to address the limitations of traditional organoid cultures. This ready-to-use, adult stem cell-derived intestinal model brings you scalability and efficiency, without the need for complex licensing or setup. Whether in your lab or through our in-house services, the OrganoReady® Colon Organoid enables flexible, high-throughput drug screening and safety studies. 👉 Swipe through to learn how this cutting-edge model can advance your research. 🔗 Learn about the OrganoReady Colon Organoid: https://lnkd.in/enab9MzJ #Organoids #Toxicology #GutResearch #Innovation #GastroIntestinalResearch

Microphysiological systems (MPS) are reshaping toxicity testing by delivering more predictive, human-relevant models. At MIMETAS, we’re pushing the boundaries of predictive toxicology with our advanced 3D tissue models, designed to bring human-relevant insights into high-throughput safety screenings. Through our services and ready-to-use models, we enable a detailed exploration of toxicity across key areas: 🧠 Blood-Brain Barrier Toxicity – Assess barrier integrity with HBMEC cells. 🩸 Vascular Toxicity – Monitor endothelial dysfunction using HUVEC models. 🧬 Intestinal Toxicity – Test gut barrier function with colon organoids. 🧪 Neurotoxicity – Detect axonal damage in iPSC-derived motor neuron models. Explore how MIMETAS can enhance your toxicity screening. Download our brochure for details: https://lnkd.in/dQ5fsGYt #MPS #ToxicityTesting #PredictiveToxicology

Our customers' trust is essential to us, and we’re proud to support their groundbreaking research. Today, we're thrilled to share feedback from Dr. Araci Rondon, Senior Researcher at Leiden University Medical Center, on the value of working with MIMETAS in their work. "By collaborating with MIMETAS scientists, we developed a 3D coculture model to study the effects of glioblastoma spheroids on blood coagulation. The OrganoPlate® platform was essential, offering the flexibility to use various tumor sources, which was crucial for our thrombosis research. The advanced 3D coculture capabilities allowed us to closely mimic the tumor microenvironment, including vasculature and perfusion between the tumor and vascular compartments, resulting in more physiologically relevant outcomes. This represents a significant improvement over traditional spheroid and monolayer cultures and enhances our ability to predict thrombus formation, a common challenge in vivo. Furthermore, the platform holds great potential for testing anticoagulant therapies and personalized medicine, with significant implications for treatment development and patient care." Thank you to Dr. Rondon and the team at LUMC for this impactful collaboration! Interested in learning how MIMETAS' 3D tissue models can advance your research? Explore our offerings here: https://lnkd.in/ejpzYH2f #CustomerTestimonial #ThrombosisResearch #3DCellCulture #PersonalizedMedicine #MicrophysiologicalSystems

Join us for an exclusive webinar on Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases, featuring Flavio Bonanini as he explores groundbreaking approaches to modeling disease progression in MASH. Discover how these innovative models are helping to evaluate the efficacy and toxicity of novel treatments, particularly in the context of comorbidities such as obesity and weight loss. 🗓️ Date: October 29 🕒 Time: 4 - 5 PM CEST In this session, you'll gain insights into how MIMETAS' advanced 3D tissue models are driving new breakthroughs in research. Learn how these predictive, human-relevant models are providing unprecedented data on disease mechanisms and therapeutic responses. 🔗Register here: https://lnkd.in/e6JRrGc5 #Webinar #DiseaseModeling #CardiovascularResearch #MetabolicDiseases